Taysha Gene Therapies, Inc.
NASDAQ:TSHA · NASDAQ Global Select
+$0.10 today
Vol 6.25M · Avg 2.73M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$109.0M -22.1% | -$89.3M +20.0% | -$111.6M +32.8% | -$166.0M +4.9% | -$174.5M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $1.1M -8.0% | $1.2M -9.2% | $1.4M +17.0% | $1.2M +138.2% | $492.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $13.3M +1.5% | $13.1M +65.8% | $7.9M -56.2% | $18.0M -0.8% | $18.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$5.4M +56.9% | -$12.5M +30.8% | -$18.0M -197.3% | $18.5M -35.4% | $28.7M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$153.0K +94.8% | -$2.9M -27.2% | -$2.3M +70.6% | -$7.8M -153.8% | $14.5M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$5.2M +45.3% | -$9.5M +39.3% | -$15.7M -159.7% | $26.3M +85.7% | $14.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $6.8M +10.4% | $6.2M -86.9% | $47.3M +18.5% | $39.9M +293.5% | $10.1M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$93.1M -14.6% | -$81.2M -11.2% | -$73.0M +17.4% | -$88.4M +24.5% | -$117.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$738.0K -97.3% | -$374.0K +94.9% | -$7.4M +70.4% | -$24.9M -15.4% | -$21.6M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $134.0K +1118.2% | $11.0K +100.3% | -$3.5M -5609.8% | -$61.0K +99.0% | -$6.3M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$604.0K -66.4% | -$363.0K +95.1% | -$7.4M +70.5% | -$24.9M -15.7% | -$21.6M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $9.2M | $0 +100.0% | -$3.5M | $0 -100.0% | $40.0M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $265.7M +246.0% | $76.8M -45.5% | $140.8M +164.4% | $53.2M +14890.0% | -$360.0K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$337.0K -251.0% | -$96.0K +89.9% | -$947.0K +17.4% | -$1.1M -123.2% | -$514.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $274.6M +258.1% | $76.7M -43.8% | $136.4M +161.8% | $52.1M +33.3% | $39.1M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $180.9M +3788.7% | -$4.9M -108.8% | $56.0M +191.5% | -$61.2M +38.5% | -$99.5M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$93.8M -15.0% | -$81.6M -1.5% | -$80.4M +29.0% | -$113.3M +18.3% | -$138.6M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.35B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.75B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.39B
Atai Beckley Inc.
NASDAQ:ATAI
$1.48B
Immatics N.V.
NASDAQ:IMTX
$1.29B
Nektar Therapeutics
NASDAQ:NKTR
$1.17B
Xencor, Inc.
NASDAQ:XNCR
$933.44M
Sana Biotechnology, Inc.
NASDAQ:SANA
$850.18M
Oculis Holding AG
NASDAQ:OCS
$636.30M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$609.62M
SEC Filings
Recent regulatory filings
No filings found.
Does TSHA generate free cash flow?
Taysha Gene Therapies, Inc. (TSHA) generated -$93,828,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does TSHA produce?
Operating cash flow was -$93,090,000.00, before capital expenditures of $738,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.